Here is the design of a clinical trial:

Official Title: Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke

Included conditions:
- Ischemic Stroke

Study Armgroups:
- {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': 'Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.\n\nDepending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes).', 'interventionNames': ['Drug: mutant pro-urokinase']}
- {'label': 'Control', 'type': 'ACTIVE_COMPARATOR', 'description': 'Usual care with alteplase 0.9 mg/kg in 60 minutes', 'interventionNames': ['Drug: Alteplase']}

Interventions:
- {'type': 'DRUG', 'name': 'mutant pro-urokinase', 'description': 'Intravenous administration', 'armGroupLabels': ['Intervention'], 'otherNames': ['HisproUK']}
- {'type': 'DRUG', 'name': 'Alteplase', 'description': 'Intravenous administration', 'armGroupLabels': ['Control'], 'otherNames': ['Actilyse']}

Primary Outcomes:
- {'measure': 'Any intracranial hemorrhage according to the Heidelberg Bleeding Classification on MRI', 'timeFrame': '24-48 hours post-treatment'}

Please estimate the sample size based on the assumption: 
The sample size will provide a power of at least 77% to detect a statistically significant effect on the primary outcome. Up to 20% of the included patients may not have a final diagnosis of ischemic stroke.
Sample size
        We will include 200 patients with a final diagnosis of ischemic stroke randomized 1:1 to either standard thrombolytic treatment or dual thrombolytic treatment. We assume that the primary outcome, any ICH, will occur with a probability of 20% with standard thrombolytic treatment and a probability of 7% in the patients treated with dual thrombolytic therapy [24]. This leads to an overall effect (odds ratio (OR)) of 0.3. This sample size will provide us with a power of at least 77% to detect a statistically significant effect on the primary outcome. This estimate does not take into account the use of multivariable adjustment for differences in baseline characteristics in the primary analysis.
        To ensure sufficient power in the targeted modified on-treatment analysis, an additional patient will be randomized and included (i.e., replaced) for each patient whodid not give consent for participation in the study, orfor any reason did not receive the full dose of thrombolytics as assigned, orhad a final diagnosis other than ischemic stroke (i.e., stroke mimic).â¦ We estimate that up to 20% of the included patients will not have a final diagnosis of ischemic stroke [25].